ADMA Biologics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- ADMA Biologics, Inc. ADMA Biologics, Inc. (ADMA) operates as an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for treating immunodeficient patients at risk for infection and others vulnerable to certain infectious diseases; its core products include three FDA-approved immune globulin therapies—ASCENIV™ (Immune Globulin Intravenous, Human – slra 10% liquid) and BIVIGAM® (Immune Globulin Intravenous, Human) for primary humoral immunodeficiency, and NABI-HB® (Hepatitis B Immune Globulin, Human) for enhanced immunity against hepatitis B virus—supported by a vertically integrated supply chain encompassing plasma collection via approximately 10 FDA-licensed ADMA BioCenters, fractionation and purification at its cGMP-compliant Boca Raton, Florida facility with up to 600,000 liters annual capacity, and contract development and manufacturing organization services. Founded in 2004 and headquartered in Ramsey, New Jersey, the company maintains U.S.-based operations focused on the immunology and infectious disease segments, targeting physicians, hospitals, infusion centers, and specialty pharmacies with its therapies derived from human plasma rich in neutralizing antibodies via proprietary microneutralization assays. Recent developments include FDA lot release authorization in 2025 for yield-enhanced commercial batches of its immune globulins to drive gross margin expansion starting in the fourth quarter, record ASCENIV demand with statistically significant real-world reductions in infection rates for primary immunodeficiency patients, advancing payer negotiations for broader 2026 reimbursement coverage, submission of a CNPV voucher application to bolster its SG-001 pipeline program, ongoing share repurchases funded organically, and a J.P. Morgan-led debt refinancing that strengthened its balance sheet with an undrawn $225 million revolver amid third-quarter 2025 revenue of $134.2 million.
Kessler Topaz Meltzer & Check, LLP - INVESTOR DEADLINE ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ADMA CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA
ADMA SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026
ROSEN, SKILLED INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
ADMA Shareholder News: ADMA Biologics Accused of Making Misrepresentations about its Revenue Sources in Securities Fraud Class Action – Investors Notified to Contact BFA Law
ADMA INVESTOR REMINDER: ADMA Biologics, Inc. Investors Have Until August 10, 2026 To Seek Lead Plaintiff Role
ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
ADMA INVESTOR ALERT: ADMA Biologics, Inc. (ADMA) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - ADMA
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit
ADMA INVESTOR ALERT: Berger Montague Advises ADMA Biologics, Inc. (ADMA) Investors of an August 10, 2026 Deadline
Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ADMA SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026